TrialInternational journal of clinical oncology2018
A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).
Taichi Takashina et al.PubMed ↗Publisher ↗
No numbers read from the abstract.